Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients.

ABSTRACT:

Background

The ability to predict ovarian function loss after anticancer treatment is important for appropriate oncofertility counseling and to aid in therapy decision-making for young women with early breast cancer (eBC).

Methods

This biomarker analysis of the BETH (NCT00625898) and KAITLIN (NCT01966471) randomized trials investigated anti-Müllerian hormone (AMH) use, alone and combined with follicle stimulating hormone (FSH) and estradiol (E2), for predicting ovarian function loss following currently adopted chemotherapy and anti-HER2 therapy in premenopausal women with HER2-positive eBC. Serum samples were centrally tested measuring AMH, FSH, and E2 using Roche Elecsys assays.

Results

Among 194 included patients (BETH: n = 62; KAITLIN: n = 132), AMH values declined

SUBMITTER: Lambertini M 

PROVIDER: S-EPMC12597502 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature